E. Ohman J or Asset Management AB Decreases Holdings in CVS Health Corporation $CVS

Key Points

• E. Ohman Jor Asset Management AB cut its CVS Health stake by 30.2% in the second quarter, selling 13,150 shares and retaining 30,455 shares valued at approximately $3.15 million.
• CVS reported strong quarterly results, with earnings of $2.58 per share versus the $1.87 consensus estimate and revenue of $106.1 billion, up 7.3% year over year.
• Analyst sentiment remains favorable: 22 analysts rate CVS a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating and an average price target of $106.46.

E. Ohman J or Asset Management AB lowered its position in CVS Health Corporation (NYSE:CVS - Free Report) by 30.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 30,455 shares of the pharmacy operator's stock after selling 13,150 shares during the quarter. E. Ohman J or Asset Management AB's holdings in CVS Health were worth $3,151,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of CVS. Norges Bank bought a new stake in shares of CVS Health in the 4th quarter worth approximately $1,666,265,000. Wellington Management Group LLP grew its holdings in shares of CVS Health by 193.2% during the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator's stock valued at $1,473,270,000 after purchasing an additional 12,233,675 shares during the last quarter. Pacer Advisors Inc. raised its position in CVS Health by 1,020.7% in the 1st quarter. Pacer Advisors Inc. now owns 4,845,221 shares of the pharmacy operator's stock worth $347,984,000 after purchasing an additional 4,412,882 shares during the period. Amundi lifted its stake in CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator's stock worth $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its position in CVS Health by 44.0% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,219,756 shares of the pharmacy operator's stock valued at $446,703,000 after buying an additional 1,899,932 shares during the period. 80.66% of the stock is currently owned by institutional investors.

Insider Activity

In other news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company's stock, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last three months, insiders sold 3,372,000 shares of company stock valued at $317,473,598. 0.85% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

CVS has been the topic of several analyst reports. Weiss Ratings upgraded CVS Health from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 5th. DA Davidson raised their price target on CVS Health from $80.00 to $100.00 and gave the stock a "buy" rating in a research report on Thursday, May 7th. Piper Sandler reaffirmed an "overweight" rating and issued a $113.00 price target on shares of CVS Health in a research note on Monday, June 1st. Wall Street Zen raised CVS Health from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Finally, Bank of America boosted their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company a "buy" rating in a research report on Monday, June 22nd. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and an average price target of $106.46.

CVS Health Price Performance

Shares of CVS Health stock opened at $93.41 on Wednesday. The business has a 50 day moving average of $102.43 and a 200 day moving average of $88.00. CVS Health Corporation has a 52 week low of $64.32 and a 52 week high of $110.68. The company has a market cap of $119.47 billion, a PE ratio of 24.71, a P/E/G ratio of 0.91 and a beta of 0.61. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.74.

CVS Health (NYSE:CVS - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share for the quarter, beating the consensus estimate of $1.87 by $0.71. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The business had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. During the same quarter in the previous year, the business posted $1.81 earnings per share. The firm's revenue for the quarter was up 7.3% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts forecast that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health's dividend payout ratio (DPR) is 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source